PK and Safety of Olodaterol + BI 54903 FDC in Healthy Volunteers

Phase 1, randomised, open-label trial of olodaterol in asthma and chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration time curve of the analyte in plasma from 0 to time t at steady state and Maximum measured concentration of the analyte in plasma at steady state. Started Apr 2009; status: completed.